VCYT
$25.36
Veracyte
$.12
.48%
VCYT
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.08)
Revenue:  $30.12 Mil
Tuesday
Jan 21
4:15 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when VCYT reports earnings?
Beat
Meet
Miss

Where is VCYT's stock price going from here?
Up
Flat
Down
Stock chart of VCYT
Analysts
Summary of analysts' recommendations for VCYT
Score
Grade
Pivots
Resistance
$26.64
$25.95
$25.59

$24.90

Support
$24.54
$23.85
$23.49
Tweet
Growth
Description
Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also developing Afirma Malignant GEC test. It serves endocrinologists, radiologists, and head and neck specialists. Veracyte, Inc. is headquartered in South San Francisco, California.
Peers
BioMarin PharmaceuticalRegeneron PharmaceuticalsVertex PharmaceuticalsCelgeneInterCeptJohnson & JohnsonMylanZoetisEndo International plcUltragenyx Pharmaceutical